SCHEMBL2812975

SCHEMBL2812975

CN(CC1CCOCC1)c1nc(-c2nc3ccccc3c(=O)o2)cs1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
HPGD P15428 3/20 0.41
F2 P00734 2/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
FFAR2 O15552 1/20 0.40
ELANE P08246 5/20 0.40
NPC1 O15118 4/20 0.39
RAB9A P51151 4/20 0.39
CSF1R P07333 1/20 0.38
MAPT P10636 2/20 0.38
TP53 P04637 1/20 0.38
C1R P00736 5/20 0.37
KDM4E B2RXH2 3/20 0.37
LMNA P02545 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
NPSR1 Q6W5P4 1/20 0.37
PLG P00747 1/20 0.37
KLK1 P06870 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2770471 0.82 CSF1R (0.43) FFAR2CSF1R
SCHEMBL23965790 0.70 NPC1 (0.42) ALDH1A1SMN1; SMN2HPGDKMT2AMEN1
SCHEMBL13634286 0.70 CSF1R (0.38) FFAR2CSF1R
SCHEMBL12352113 0.70 ELANE (0.58) ALDH1A1SMN1; SMN2HPGDF2KMT2A
SCHEMBL2770812 0.69 CSF1R (0.39) ALDH1A1KMT2AFFAR2NPC1RAB9A
SCHEMBL13270614 0.65 FFAR2 (0.36) KMT2AFFAR2NPC1RAB9ACSF1R
SCHEMBL13162766 0.65 CSF1R (0.43) SMN1; SMN2KMT2AFFAR2NPC1RAB9A
SCHEMBL272287 0.64 ELANE (0.81) ALDH1A1SMN1; SMN2HPGDF2KMT2A
SCHEMBL12352106 0.64 ELANE (0.69) ALDH1A1SMN1; SMN2HPGDF2KMT2A
SCHEMBL12352121 0.62 ELANE (0.67) ALDH1A1SMN1; SMN2HPGDF2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2206707-B1 AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF ASTELLAS PHARMA INC (JP) 2014-07-23 EP disclosed
EP-2206707-B1 AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF ASTELLAS PHARMA INC (JP) 2014-07-23 EP disclosed
US-8304547-B2 Azolecarboxamide compound or salt thereof ASTELLAS PHARMA INC. (JP) 2012-11-06 US disclosed
US-8304547-B2 Azolecarboxamide compound or salt thereof ASTELLAS PHARMA INC. (JP) 2012-11-06 US disclosed
US-8304547-B2 Azolecarboxamide compound or salt thereof ASTELLAS PHARMA INC. (JP) 2012-11-06 US disclosed
US-20100249088-A1 AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2010-09-30 US disclosed
US-20100249088-A1 AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2010-09-30 US disclosed
EP-2206707-A1 AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF Astellas Pharma Inc. (JP) 2010-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249088-A1 AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF TRPV1, FGFR3, GPR17 ALDH1A1 1659/4885SMN1; SMN2 3213/4885HPGD 1224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.